Oligodendroglioma: A Review of Management and Pathways

Maroun Bou Zerdan; Hazem I Assi

doi:10.3389/fnmol.2021.722396

Oligodendroglioma: A Review of Management and Pathways

Front Mol Neurosci. 2021 Oct 5:14:722396. doi: 10.3389/fnmol.2021.722396. eCollection 2021.

Authors

Maroun Bou Zerdan¹, Hazem I Assi¹

Affiliation

¹ Division of Hematology and Oncology, Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.

Abstract

Anaplastic oligodendrogliomas are a type of glioma that occurs primarily in adults but are also found in children. These tumors are genetically defined according to the mutations they harbor. Grade II and grade III tumors can be differentiated most of the times by the presence of anaplastic features. The earliest regimen used for the treatment of these tumors was procarbazine, lomustine, and vincristine. The treatment modalities have shifted over time, and recent studies are considering immunotherapy as an option as well. This review assesses the latest management modalities along with the pathways involved in the pathogenesis of this malignancies.

Keywords: IDH mutation; PCV; anaplastic oligodendroglioma; lomustine; procarbazine; temozolomide; vincristine.

Publication types

Review